


PHARMACEUTICAL 2023











PHARMACEUTICAL 2023



Altimmune Inc. Rank 92 of 446



The relative strengths and weaknesses of Altimmune Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Altimmune Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 86% points. The greatest weakness of Altimmune Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 205%, being 162% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	192,813
Cost of Goods Sold	0
Intangible Assets	12,419
Liabilities, Current	17,054
Liabilities, Non-Current	0
Other Assets	615
Other Compr. Net Income	-187
Other Expenses	-197
Other Liabilities	4,581
Other Net Income	2,830
Other Revenues	-68
Property and Equipment	1,081
Research and Development	70,538
Selling, General and Administrative Expense	17,134

Output Variable	Value in 1000 USD
Assets	206,928
Liabilities	21,635
Expenses	87,475
Revenues	-68
Stockholders Equity	185,293
Net Income	-84,713
Comprehensive Net Income	-84,806
Economic Capital Ratio	205%

